ReviewJournal of oncology2022
Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment.
Review in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 65 citations in OpenAlex.
- Article
- Male breast cancer: from extrapolated practice to evidence-based care.The oncologist · 2026Review
- Male Breast Cancer: Bridging the Gaps of Neglect-A Global Call for Equitable Care and Inclusion.Health science reports · 2026Article
- Male Breast Cancer: Growing Insights and Continuing Challenges.Cancer medicine · 2026Review
- Genomic landscape, immune microenvironment and survival in male versus female breast cancer.ESMO open · 2026Article
- Article
- The Effect of Clinicopathological Features and Postoperative Management on Prognosis in Male Breast Cancer.The breast journal · 2026Article
- Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition).Cancer innovation · 2025Article
- Article
- Article
- A protocol for three observational cohort studies evaluating adverse outcomes, excess costs and repeat procedures after surgery for breast cancer in the USA.Journal of comparative effectiveness research · 2025Article
- Mitigated deployment strategy for ethical AI in clinical settings.BMJ health & care informatics · 2025Article
- Development, verification, and comparison of a risk stratification model to identify potential population benefiting from chemotherapy in non-metastatic male breast cancer.Scientific reports · 2025Article
- Article
- CDK4/6 as a Therapeutic Target in HR+/HER2- Breast Cancer Cells-Current Treatment Status.Cancers · 2025Review
- Decoding male breast cancer: epidemiological insights, cutting-edge treatments, and future perspectives.Discover oncology · 2025Review
- Treatments of Interest in Male Breast Cancer: An Umbrella Review.Journal of personalized medicine · 2025Review
- Comprehensive review of male breast cancer: Understanding a rare condition.Oncology research · 2025Review
- Case Report: FatalCase reports in oncological medicine · 2025Article
- Breast cancer burden (1990-2040) in individuals aged 55 and above: a GBD 2021 analysis of global trends, sex-specific risk factors, and intervention impact.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male breast cancer (MaBC) is a rare clinical entity, which makes up approximately 1% of all breast cancers. However, the incidence of MaBC has been steadily increasing over the past few decades. The risk factors for MaBC include age, black race, family history of breast cancer, genetic mutations, liver cirrhosis, and testicular abnormalities. The majority of patients with MaBC present with painless lumps, and about half of the patients have at least one lymph node involved at the time of diagnosis. The treatment of MaBC models that of female breast cancer (FeBC), but this is mainly due to lack of prospective studies for MaBC patients. The treatment modality includes surgery, adjuvant radiation, endocrine therapy, and chemotherapy. However, there are some distinct features of MaBC, both clinically and molecularly, that may warrant a different clinical approach. Ongoing multinational effort is required, to conduct clinical trials for MaBC, or the inclusion of MaBC patients in FeBC trials, to help clinicians improve care for MaBC patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.